Introduction
The lung is a highly perfused, hyper-oxygenated organ in which the microenvironment plays a key role in response to the many environmental insults that it is constantly exposed to. This includes the rapid recruitment of inflammatory cells following injury, with chronic inflammatory response altering microenvironmental stimuli in favour of a pro-carcinogenic environment. In established cancers, tumour cells interact with the complex milieu that is the tumour microenvironment, consisting of extracellular matrix (ECM), cytokines, vasculature-related cells (eg, smooth muscle cells), immune cells (eg, macrophages, lymphocytes) and fibroblasts 1 . Permissive within this environment, is the activation of the fibroblastic cellular component to gain a myofibroblast-like sub-type resulting from acquisition of pre-malignant changes within neighbouring epithelial cells. The pathways by which fibroblast activation occurs are not well described, but may be dependent upon v6 integrin/ Transforming Growth Factor  (TGF) signalling, maintained via tumour cells expressing E-cadherin and Epithelial Cellular Adhesion Molecule (EpCAM) 2 .
These tumour-activated or Cancer Associated Fibroblasts (CAFs) secrete many matrix remodelling proteins including collagen, fibronectin, laminin and tenascin Within this review, we summarise the known interactions between lung epithelia and surrounding reactive fibroblasts, highlighting the need to further investigate CAFs as therapeutic targets in lung cancer chemoprevention strategies.
Interaction of fibroblasts with lung stem cells
In the healthy lung, lung stem cells are able to engage and recruit fibroblasts via paracrine signalling through stromal derived factor-1 (SDF-1). The fibroblasts are required by the stem cells to elicit their proliferative response, and to maintain a functional stem cell microenvironment. SDF-1 is itself regulated by fibroblast-secreted TNFwhich is in turn tightly regulated by p38 4 . Similarly, lung cancer stem cells also rely on fibroblasts to maintain a functional stem cell niche in which they can maintain their self-renewing stemlike phenotype. It was recently observed that removal of CAFs from lung cancer stem cell cocultures resulted in down-regulation of the characteristic stemness-associated genes Oct3/4
and Nanog, resulting in much reduced tumour initiating frequency in the lung cancer stem cells. CAF-secreted cytokines that impacted on regulation of stemness genes included IGF-II, CD14 and HGF 5 . It is also likely that paracrine signalling via fibroblasts further contributes to the stem-like signature of lung cancer cells by induction of TGF--mediated epithelial to mesenchymal transition (EMT) 6 .
CAFs in lung cancer
The origins of activated fibroblasts within the tumour stroma are ambiguous. It has been proposed that they may arise from a variety of originator cell types, including resident fibroblasts, bone marrow-derived progenitor cells, or epithelial cells that have undergone epithelial to mesenchymal transition to gain a myofibroblast-like phenotype 7, 8 . However, there is growing evidence that the origins of CAFs in lung cancer arise directly from reprogramming of resident fibroblasts, rather than from non-stromal sources or from a permissive stromal environment allowing for clonal expansion of rare fibroblast subsets exhibiting a CAF phenotype 9 . Characterisation of lung CAF ultrastructure reveals higher expression of intracellular -smooth muscle actin (-SMA) and extracellular bundles of fibronectin, associated with greater collagen gel contractility (a measure of matrix remodelling capacity) and invasive capacity compared to normal lung fibroblasts 10, 11 . CAFs also have higher basal levels of autophagy compared to their normal fibroblast counterparts, which may promote survival and protect against oxidative damage 12 or therapeutic intervention, allowing continued pro-carcinogenic signalling to adjacent tumour epithelium.
More extensive CAF characterisation has recently been undertaken using desmoplastic mouse mammary carcinoma models. Here, the mechanical stress-activated transcriptional regulator
Yes-Associated Protein (YAP) exhibited nuclear localisation (maintained by Src) and was observed to be activated in CAFs, with the ability of CAFs to promote tumour cell invasion dependent upon YAP activation 13 . Furthermore, nuclear translocation of YAP in CAFs was observed in pre-malignant models of breast cancer, suggesting a potential target for preventive strategies. Whilst this has yet to be observed in lung cancer models, growing evidence suggests that YAP-mediated ECM remodelling by CAFs is able to cause progressively stiffer matrices that drive tumour progression, and that this is likely to translate across a variety of tumour types 14 .
In vivo evidence of a role for CAFs in driving tumour development arises from orthotopic and xenograft mouse models. Here, CAFs in co-culture with epithelial tumour cells exhibit significantly larger tumour volumes and faster growth rates compared with xenografts of tumour cells alone 9 . Additionally, xenograft co-culture models exhibit strong pro-inflammatory and angiogenic paracrine signalling 15 Investigating interaction of CAFs with tumour cells and other cellular components of stromal matrices has increasingly been undertaken using co-culture models to demonstrate the extensive cross-talk between the cell types, and are summarised in Table 1 5, 11, 21, 27-60 , with an overview of these interactions in figure 1 .
Relevance of CAFs in prognosis
Clinically, there is accumulating evidence which implies prognostic relevance for CAFs in several malignancies including Non-Small Cell Lung Cancer (NSCLC) [61] [62] [63] 
Role of CAFs in therapeutic resistance
Lung cancers that exhibit EGFR activating mutations are treated with small molecule EGFR tyrosine kinase inhibitors (TKI) such as gefitinib or erlotinib. TKIs are also often used in maintenance therapy to improve progression free survival and may have potential in the adjuvant setting. However, some patients exhibit intrinsic resistance to these TKIs, and most individuals will eventually acquire TKI resistance, ultimately resulting in treatment failure. 
Targeting of CAF-related signalling pathways
Variable responses of CAFs to a variety cytotoxic drugs have reported, dictated by many factors including cancer type and microenvironment composition 76 . Dense desmoplastic stromal environments such as that observed in lung cancer exhibit poor drug penetrance properties, thus the tumour microenvironment plays a critical role in dictating efficacy of interventional drugs. If the extracellular matrix of the tumour could be modified, then drug penetration into the tumour might be facilitated. Table 2 to targeted therapies 87 . The IL-6 neutralising antibody Siltuximab was observed to suppress fibroblast IL-6-induced STAT3 phosphorylation and activation in NSCLC cell lines in vitro and in vivo 80, 88 , but lacked observable clinical activity in a number of different solid tumours 89 . Similarly, Sibrotuzumab, a promising humanised monoclonal antibody targeting fibroblast activation protein 81 , lacked observable clinical efficacy in a phase II trial for metastatic colorectal cancer 90 . Inhibitors directed against Met activation by HGF blockade, include the anti-HGF antibody Rilotumumab (AMG 102), which has recently been evaluated in oesopho-gastric cancers in combination with epirubicin, cisplatin and capecitebine (ECX).
Here, greater efficacy was observed in the Rilotumumab + ECX group than placebo + ECX group 82 .
The potential for chemopreventive strategies to influence fibroblast-mediated models of disease, remains relatively unexplored. Chemoprevention models for breast cancer have utilised the mTOR inhibitor, rapamycin, to decrease stromal content of mammary tumours, rendering the microenvironment less suitable for tumour growth and progression 83 .
Curcuminoids (<100 nM) were able to block ECM deposition and TGF-/p-SMAD-2 signalling pathways in keloid, a fibrotic disease characterised by the abnormal accumulation of ECM in the dermis 84 , with further evidence for anti-fibrotic effects observed following inhibition of the bleomycin-induced fibrotic progression in the mouse lung 85 . Another compound with potential anti-fibrotic activity is the tea polyphenol Epigallocatechin Gallate (EGCG), which inhibited TGF-mediated oral submucous fibrosis via suppression of p-38 mitogen activated protein kinase (p-38 MAPK) and c-jun NH2-terminal kinase (JNK) phosphorylation 86 . Recently, the Src kinase inhibitor Saracatinib (AZD0530) was shown to prevent TGF- -induced Src activation in human lung fibroblasts, preventing transition to a myofibroblast phenotype 91 .
Many agents being investigated for their putative cancer chemopreventive properties, have been shown to exert effects on the signalling pathways described above, across many tumour models. Such agents, which may have potential for utility in lung cancer chemoprevention strategies include statins, non-steroidal anti-inflammatories (NSAIDS), metformin, tea polyphenols, curcumin and carotenoids [92] [93] [94] [95] [96] [97] . To date, the mechanistic focus for these agents has been on their ability to directly inhibit pro-carcinogenic signalling pathways within the tumour cells themselves, whereas there is great potential for chemopreventive strategies to target ECM remodelling capabilities of fibroblasts. This in turn would decrease pro-carcinogenic paracrine signalling to adjacent epithelia, in addition to preventing cultivation of ECM niches permissive for tumour growth and invasion.
Ultimately, primary prevention strategies for lung cancer must be targeted towards smoking cessation, yet chemoprevention via pharmacological means remains attractive for those cohorts at high risk for either primary lung cancer, or lung cancer recurrence and metastatic spread. Targeting desmosplasia and the complex paracrine signalling networks between the epithelia and fibroblastic constituents in inflammatory fibrotic or malignant disease offers an attractive target for evaluation in future pharmacologic prevention strategies. 2013 Choe C et al.
Tissues from patients with resected NSCLC To investigate the differential contribution of direct cell-cell contact and paracrine signalling factors to NSCLC metastases 1) CAFs potently induce EMT in NSCLC H358 cells through direct contact 2) H358 cells in direct contact with CAFs up-regulate the expression of the pan-mesenchymal markers α-SMA, FAP, TGFβ, SMAD3 and hedgehog signalling effector GLI family zinc finger-1 (GLI1) 3) Snail family zinc finger-1 (SNAI1) and SNAI2 are upregulated, suggesting that the hedgehog signalling pathway is active in direct co-culture 35 
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Tissues from patients with resected NSCLC To examine the role of CAFs in NSCLC tumour progression 1) CAFs exhibited greater expression of α-SMA than normal fibroblasts (NFs) 2) CAFs were more potent in inducing the EMT phenotype than NFs which led to increased motility and decreased proliferation of NSCLC cells via SMAD3 dependent upregulation of p21(CIP1), CDKN1A and α-SMA 36 2012 Horie. M et al.
Tumour and non-tumour resected from NSCLC patient Characterization of human lung CAFs in 3D in vitro co-culture model 1) CAFs showed higher α-SMA expression than NFs 2) CAFs enhanced and were more potent in inducing collagen gel contraction compared to NFs 3) CAFs had more potential to increase invasion of A549 cells compared to NFs. Fujita H et al.
MRC5
To establish a co-culture system that could be used to quantify populations of cancer cells in co-culture with pancreatic stellate cells (PSC)s 1) MRC5 enhanced proliferation of pancreatic cancer cells, induced EMT-like morphological change and activated the Notch signalling pathway 2) The co-culture system can be used to quantitatively and reproducibly to evaluate GFP-expressing cell populations 
NHLFs
To investigate the interaction of NHLFs and alveolar 1) CCL18 production by alveolar macrophages was significantly higher in co-culture than in alveolar 
